BINASCHI, MONICA
 Distribuzione geografica
Continente #
NA - Nord America 102
AS - Asia 97
EU - Europa 38
SA - Sud America 16
AF - Africa 10
Totale 263
Nazione #
US - Stati Uniti d'America 99
SG - Singapore 40
HK - Hong Kong 18
IT - Italia 15
VN - Vietnam 13
CN - Cina 11
BR - Brasile 10
IN - India 6
FR - Francia 5
FI - Finlandia 4
ZA - Sudafrica 4
AR - Argentina 3
DE - Germania 3
MA - Marocco 3
AT - Austria 2
CO - Colombia 2
EG - Egitto 2
ID - Indonesia 2
IQ - Iraq 2
MX - Messico 2
PL - Polonia 2
RU - Federazione Russa 2
AM - Armenia 1
BD - Bangladesh 1
CA - Canada 1
ES - Italia 1
GB - Regno Unito 1
JP - Giappone 1
KR - Corea 1
NL - Olanda 1
PH - Filippine 1
RO - Romania 1
SE - Svezia 1
TG - Togo 1
VE - Venezuela 1
Totale 263
Città #
Hong Kong 18
Singapore 18
Ashburn 15
Santa Clara 9
San Jose 7
Buffalo 5
Ho Chi Minh City 5
Beijing 4
Houston 4
North Charleston 4
Rome 4
Fairfield 3
Helsinki 3
Johannesburg 3
Los Angeles 3
New York 3
São Paulo 3
Ardea 2
Cairo 2
Cambridge 2
Chandler 2
Cosenza 2
Da Nang 2
Dallas 2
Frankfurt am Main 2
Hanoi 2
Hefei 2
Jakarta 2
Lauterbourg 2
Seattle 2
Wilmington 2
Woodbridge 2
Ann Arbor 1
Atlanta 1
Baghdad 1
Bari 1
Belo Horizonte 1
Bengaluru 1
Benito Juarez 1
Boardman 1
Boston 1
Botuporã 1
Brasília 1
Bucharest 1
Butuan 1
Cancún 1
Casablanca 1
Chicago 1
Cleveland 1
Columbus 1
Da Lat 1
Delaware 1
Denver 1
El Tigre 1
Federal 1
Florence 1
Franklinville 1
Hillsboro 1
Kunming 1
Lanús 1
Lappeenranta 1
Las Vegas 1
Lawrence 1
Lomé 1
Madrid 1
Materlândia 1
Medellín 1
Milan 1
Mosul 1
New Delhi 1
Nuremberg 1
Ogden 1
Parnamirim 1
Pitalito 1
Princeton 1
Qingdao 1
San Diego 1
San Paolo di Civitate 1
Santo André 1
Santo Antônio 1
Seoul 1
Sidi Allal El Bahraoui 1
Tampa 1
Thái Nguyên 1
Tokyo 1
Toronto 1
Vienna 1
Villa María 1
Warsaw 1
Yerevan 1
Totale 199
Nome #
MEN1309/OBT076, a first-in-class antibody–drug conjugate targeting CD205 in solid tumors 129
Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer 91
Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups 53
Totale 273
Categoria #
all - tutte 790
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 790


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20229 0 0 2 0 1 0 0 2 1 0 2 1
2022/202310 3 3 0 0 1 1 0 0 0 2 0 0
2023/202415 0 1 0 0 1 4 0 0 0 2 2 5
2024/202573 1 0 1 3 14 1 4 4 12 9 9 15
2025/2026146 7 12 8 9 20 5 24 12 8 14 8 19
Totale 273